Skeletal Muscle Relaxants

May 8, 2026

Upload by Patrick

This document provides comprehensive information on skeletal muscle relaxants, detailing their mechanisms of action, indications, and potential interactions. It highlights that many of these drugs achieve symptom relief through their sedative effects rather than direct muscle relaxation, with cyclobenzaprine specifically noted for its impact on muscle tone and reduction of spasms. The document outlines their primary use in managing acute painful musculoskeletal conditions like muscle strains and back pain. A significant portion is dedicated to drug interactions, particularly the heightened CNS depressant effects when combined with alcohol, antihistamines, opiates, and sedatives. Specific contraindications are listed for various relaxants: cyclobenzaprine is to be avoided in patients with recent myocardial infarction, cardiac conduction disorders, and hyperthyroidism, and within 14 days of MAOI administration; oral dantrolene is contraindicated during lactation and in active hepatic disease; baclofen is not recommended for spasms caused by rheumatic disorders; and carisoprodol carries contraindications for those hypersensitive to meprobamate. Common side effects such as drowsiness, sedation, sleepiness, lethargy, constipation, diarrhea, bradycardia or tachycardia, and rash are enumerated. The document also includes crucial warnings for patients, advising against driving or hazardous tasks if drowsiness occurs, limiting use to 2-3 weeks, and strictly avoiding concurrent use of alcohol or other CNS depressants.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages1

Reading Time3 min

AccessFree to download

May 8, 2026

Upload by Patrick